B-intervention	0	5	Globo
I-intervention	6	7	H
I-intervention	7	8	-
I-intervention	8	11	KLH
I-intervention	12	19	vaccine
I-intervention	20	29	adagloxad
I-intervention	30	39	simolenin
O	40	41	(
O	41	44	OBI
O	44	45	-
O	45	48	822
O	48	49	)
O	49	50	/
O	50	53	OBI
O	53	54	-
O	54	57	821
O	58	60	in
O	61	69	patients
O	70	74	with
O	75	85	metastatic
O	86	92	breast
O	93	99	cancer
O	99	100	:
O	101	106	phase
O	107	109	II
O	110	120	randomized
O	120	121	,
O	122	129	placebo
O	129	130	-
O	130	140	controlled
O	141	146	study
O	146	147	.

O	148	152	This
O	153	163	randomized
O	163	164	,
O	165	171	double
O	171	172	-
O	172	177	blind
O	177	178	,
O	179	186	placebo
O	186	187	-
O	187	197	controlled
O	197	198	,
O	199	207	parallel
O	207	208	-
O	208	213	group
O	213	214	,
O	215	220	phase
O	221	223	II
O	224	229	trial
O	230	238	assessed
O	239	242	the
O	243	251	efficacy
O	252	255	and
O	256	262	safety
O	263	265	of
O	266	275	adagloxad
O	276	285	simolenin
O	286	287	(
O	287	290	OBI
O	290	291	-
O	291	294	822
O	294	295	;
O	296	297	a
O	298	303	Globo
O	304	305	H
O	306	313	epitope
O	314	324	covalently
O	325	331	linked
O	332	334	to
O	335	342	keyhole
O	343	349	limpet
O	350	360	hemocyanin
O	361	362	(
O	362	365	KLH
O	365	366	)
O	366	367	)
O	368	372	with
O	373	381	adjuvant
O	382	385	OBI
O	385	386	-
O	386	389	821
O	390	392	in
O	393	403	metastatic
O	404	410	breast
O	411	417	cancer
O	418	419	(
O	419	422	MBC
O	422	423	)
O	423	424	.

O	425	427	At
O	428	430	40
O	431	436	sites
O	437	439	in
B-location	440	446	Taiwan
I-location	446	447	,
I-location	448	451	USA
I-location	451	452	,
I-location	453	458	Korea
I-location	458	459	,
I-location	460	465	India
I-location	465	466	,
I-location	467	470	and
I-location	471	475	Hong
I-location	476	480	Kong
O	480	481	,
B-eligibility	482	490	patients
I-eligibility	491	495	with
I-eligibility	496	499	MBC
I-eligibility	500	502	of
I-eligibility	503	506	any
I-eligibility	507	516	molecular
I-eligibility	517	524	subtype
I-eligibility	525	528	and
I-eligibility	529	530	≤
I-eligibility	530	531	2
I-eligibility	532	537	prior
I-eligibility	538	549	progressive
I-eligibility	550	557	disease
I-eligibility	558	564	events
I-eligibility	565	569	with
I-eligibility	570	576	stable
I-eligibility	576	577	/
I-eligibility	577	587	responding
I-eligibility	588	595	disease
I-eligibility	596	601	after
I-eligibility	602	605	the
I-eligibility	606	610	last
I-eligibility	611	621	anticancer
I-eligibility	622	629	regimen
O	630	634	were
O	635	645	randomized
O	646	647	(
O	647	648	2
O	648	649	:
O	649	650	1
O	650	651	)
O	652	654	to
O	655	664	adagloxad
O	665	674	simolenin
O	675	676	(
O	676	678	AS
O	678	679	/
O	679	682	OBI
O	682	683	-
O	683	686	821
O	686	687	)
O	688	690	or
B-control	691	698	placebo
O	698	699	,
O	700	714	subcutaneously
O	715	718	for
O	719	723	nine
O	724	729	doses
O	730	734	with
O	735	738	low
O	738	739	-
O	739	743	dose
O	744	760	cyclophosphamide
O	760	761	.

O	762	765	The
O	766	773	primary
O	774	782	endpoint
O	783	786	was
B-outcome-Measure	787	798	progression
I-outcome-Measure	798	799	-
I-outcome-Measure	799	803	free
I-outcome-Measure	804	812	survival
I-outcome-Measure	813	814	(
I-outcome-Measure	814	817	PFS
I-outcome-Measure	817	818	)
O	818	819	.

O	820	829	Secondary
O	830	839	endpoints
O	840	848	included
B-outcome-Measure	849	856	overall
I-outcome-Measure	857	865	survival
O	865	866	,
B-outcome-Measure	867	878	correlation
I-outcome-Measure	879	881	of
I-outcome-Measure	882	890	clinical
I-outcome-Measure	891	898	outcome
I-outcome-Measure	899	903	with
I-outcome-Measure	904	911	humoral
I-outcome-Measure	912	918	immune
I-outcome-Measure	919	927	response
I-outcome-Measure	928	931	and
I-outcome-Measure	932	937	Globo
I-outcome-Measure	938	939	H
I-outcome-Measure	940	950	expression
O	950	951	,
O	952	955	and
B-outcome-Measure	956	962	safety
O	962	963	.

O	964	966	Of
B-total-participants	967	970	349
O	971	979	patients
O	980	990	randomized
O	990	991	,
B-total-participants	992	995	348
O	996	1004	received
O	1005	1010	study
O	1011	1015	drug
O	1015	1016	.

O	1017	1025	Patients
O	1026	1030	with
O	1031	1034	the
O	1035	1044	following
O	1045	1051	breast
O	1052	1058	cancer
O	1059	1067	subtypes
O	1068	1072	were
O	1073	1081	included
O	1081	1082	:
O	1083	1090	hormone
O	1091	1099	receptor
O	1099	1100	-
O	1100	1108	positive
O	1109	1110	(
O	1110	1112	HR
O	1112	1113	+
O	1113	1114	)
O	1114	1115	/
O	1115	1120	human
O	1121	1130	epidermal
O	1131	1137	growth
O	1138	1144	factor
O	1145	1153	receptor
O	1154	1155	2
O	1155	1156	-
O	1156	1164	negative
O	1165	1166	(
O	1166	1170	HER2
O	1170	1171	-
O	1171	1172	)
O	1173	1174	(
O	1174	1176	70
O	1176	1177	.
O	1177	1178	4
O	1178	1179	%
O	1179	1180	)
O	1180	1181	,
O	1182	1188	triple
O	1189	1197	negative
O	1198	1199	(
O	1199	1201	12
O	1201	1202	.
O	1202	1203	9
O	1203	1204	%
O	1204	1205	)
O	1205	1206	,
O	1207	1210	and
O	1211	1215	HER2
O	1215	1216	+
O	1217	1218	(
O	1218	1220	16
O	1220	1221	.
O	1221	1222	7
O	1222	1223	%
O	1223	1224	)
O	1224	1225	,
O	1226	1235	similarly
O	1236	1247	distributed
O	1248	1255	between
O	1256	1265	treatment
O	1266	1270	arms
O	1270	1271	.

B-outcome	1272	1278	Median
I-outcome	1279	1282	PFS
O	1283	1286	was
O	1287	1288	7
O	1288	1289	.
O	1289	1290	6
O	1291	1297	months
O	1298	1299	(
O	1299	1301	95
O	1301	1302	%
O	1303	1305	CI
O	1305	1306	:
O	1307	1308	6
O	1308	1309	.
O	1309	1310	5
O	1310	1311	-
O	1311	1313	10
O	1313	1314	.
O	1314	1315	9
O	1315	1316	)
O	1317	1321	with
O	1322	1324	AS
O	1324	1325	/
O	1325	1328	OBI
O	1328	1329	-
O	1329	1332	821
O	1333	1334	(
O	1334	1335	n
O	1335	1336	=
B-intervention-participants	1336	1339	224
O	1339	1340	)
O	1341	1344	and
O	1345	1346	9
O	1346	1347	.
O	1347	1348	2
O	1349	1355	months
O	1356	1357	(
O	1357	1359	95
O	1359	1360	%
O	1361	1363	CI
O	1363	1364	:
O	1365	1366	7
O	1366	1367	.
O	1367	1368	3
O	1368	1369	-
O	1369	1371	11
O	1371	1372	.
O	1372	1373	3
O	1373	1374	)
O	1375	1379	with
O	1380	1387	placebo
O	1388	1389	(
O	1389	1390	n
O	1390	1391	=
B-control-participants	1391	1394	124
O	1394	1395	)
O	1396	1397	(
O	1397	1399	HR
O	1399	1400	=
O	1400	1401	0
O	1401	1402	.
O	1402	1404	96
O	1404	1405	;
O	1406	1408	95
O	1408	1409	%
O	1410	1412	CI
O	1412	1413	:
O	1414	1415	0
O	1415	1416	.
O	1416	1418	74
O	1418	1419	-
O	1419	1420	1
O	1420	1421	.
O	1421	1423	25
O	1423	1424	;
O	1425	1426	p
O	1426	1427	=
O	1427	1428	0
O	1428	1429	.
O	1429	1431	77
O	1431	1432	)
O	1432	1433	,
O	1434	1438	with
O	1439	1441	no
O	1442	1452	difference
O	1453	1455	by
O	1456	1462	breast
O	1463	1469	cancer
O	1470	1477	subtype
O	1477	1478	.

O	1479	1481	AS
O	1481	1482	/
O	1482	1485	OBI
O	1485	1486	-
O	1486	1489	821
O	1490	1500	recipients
O	1501	1505	with
O	1506	1510	anti
O	1510	1511	-
O	1511	1516	Globo
O	1517	1518	H
O	1519	1522	IgG
O	1523	1528	titer
O	1529	1530	≥
O	1530	1531	1
O	1531	1532	:
O	1532	1535	160
O	1536	1539	had
O	1540	1553	significantly
O	1554	1560	longer
B-outcome	1561	1567	median
I-outcome	1568	1571	PFS
O	1572	1573	(
O	1573	1575	11
O	1575	1576	.
O	1576	1577	1
O	1578	1584	months
O	1585	1586	(
O	1586	1588	95
O	1588	1589	%
O	1590	1592	CI
O	1592	1593	:
O	1594	1595	9
O	1595	1596	.
O	1596	1597	3
O	1597	1598	-
O	1598	1600	17
O	1600	1601	.
O	1601	1602	6
O	1602	1603	)
O	1603	1604	)
O	1605	1611	versus
O	1612	1617	those
O	1618	1622	with
O	1623	1629	titers
O	1630	1631	<
O	1631	1632	1
O	1632	1633	:
O	1633	1636	160
O	1637	1638	(
O	1638	1639	5
O	1639	1640	.
O	1640	1641	5
O	1642	1648	months
O	1649	1650	(
O	1650	1652	95
O	1652	1653	%
O	1654	1656	CI
O	1656	1657	:
O	1658	1659	3
O	1659	1660	.
O	1660	1661	7
O	1661	1662	-
O	1662	1663	5
O	1663	1664	.
O	1664	1665	6
O	1665	1666	)
O	1666	1667	;
O	1668	1670	HR
O	1670	1671	=
O	1671	1672	0
O	1672	1673	.
O	1673	1675	52
O	1675	1676	;
O	1677	1678	p
O	1678	1679	<
O	1679	1680	0
O	1680	1681	.
O	1681	1685	0001
O	1685	1686	)
O	1687	1690	and
O	1691	1698	placebo
O	1699	1709	recipients
O	1710	1711	(
O	1711	1713	HR
O	1713	1714	=
O	1714	1715	0
O	1715	1716	.
O	1716	1718	71
O	1718	1719	;
O	1720	1721	p
O	1721	1722	=
O	1722	1723	0
O	1723	1724	.
O	1724	1726	03
O	1726	1727	)
O	1727	1728	.

B-outcome	1729	1733	Anti
I-outcome	1733	1734	-
I-outcome	1734	1737	KLH
I-outcome	1738	1744	immune
I-outcome	1745	1754	responses
O	1755	1759	were
O	1760	1767	similar
O	1768	1770	at
O	1771	1775	week
O	1776	1778	40
O	1779	1786	between
O	1787	1789	AS
O	1789	1790	/
O	1790	1793	OBI
O	1793	1794	-
O	1794	1797	821
O	1798	1808	recipients
O	1809	1813	with
O	1814	1818	anti
O	1818	1819	-
O	1819	1824	Globo
O	1825	1828	IgG
O	1829	1834	titer
O	1835	1836	≥
O	1836	1837	1
O	1837	1838	:
O	1838	1841	160
O	1842	1845	and
O	1846	1851	those
O	1852	1856	with
O	1857	1861	anti
O	1861	1862	-
O	1862	1867	Globo
O	1868	1871	IgG
O	1872	1877	titer
O	1878	1879	<
O	1879	1880	1
O	1880	1881	:
O	1881	1884	160
O	1884	1885	.

O	1886	1889	The
O	1890	1894	most
O	1895	1901	common
O	1902	1909	adverse
O	1910	1916	events
O	1917	1921	with
O	1922	1924	AS
O	1924	1925	/
O	1925	1928	OBI
O	1928	1929	-
O	1929	1932	821
O	1933	1937	were
B-outcome	1938	1943	grade
I-outcome	1944	1945	1
I-outcome	1946	1948	or
I-outcome	1949	1950	2
I-outcome	1951	1960	injection
I-outcome	1961	1965	site
I-outcome	1966	1975	reactions
O	1976	1977	(
B-iv-bin-percent	1977	1979	56
I-iv-bin-percent	1979	1980	.
I-iv-bin-percent	1980	1981	7
I-iv-bin-percent	1981	1982	%
O	1982	1983	;
O	1984	1991	placebo
O	1991	1992	,
B-cv-bin-percent	1993	1994	8
I-cv-bin-percent	1994	1995	.
I-cv-bin-percent	1995	1996	9
I-cv-bin-percent	1996	1997	%
O	1997	1998	)
O	1999	2002	and
B-outcome	2003	2008	fever
O	2009	2010	(
B-iv-bin-percent	2010	2012	20
I-iv-bin-percent	2012	2013	.
I-iv-bin-percent	2013	2014	1
I-iv-bin-percent	2014	2015	%
O	2015	2016	;
O	2017	2024	placebo
O	2024	2025	,
B-cv-bin-percent	2026	2027	6
I-cv-bin-percent	2027	2028	.
I-cv-bin-percent	2028	2029	5
I-cv-bin-percent	2029	2030	%
O	2030	2031	)
O	2031	2032	.

O	2033	2035	AS
O	2035	2036	/
O	2036	2039	OBI
O	2039	2040	-
O	2040	2043	821
O	2044	2047	did
O	2048	2051	not
O	2052	2059	improve
B-outcome	2060	2063	PFS
O	2064	2066	in
O	2067	2075	patients
O	2076	2080	with
O	2081	2091	previously
O	2092	2099	treated
O	2100	2103	MBC
O	2103	2104	.

O	2105	2112	However
O	2112	2113	,
O	2114	2121	humoral
O	2122	2128	immune
O	2129	2137	response
O	2138	2140	to
O	2141	2146	Globo
O	2147	2148	H
O	2149	2159	correlated
O	2160	2164	with
O	2165	2173	improved
O	2174	2177	PFS
O	2178	2180	in
O	2181	2183	AS
O	2183	2184	/
O	2184	2187	OBI
O	2187	2188	-
O	2188	2191	821
O	2192	2202	recipients
O	2202	2203	,
O	2204	2211	leading
O	2212	2215	the
O	2216	2219	way
O	2220	2222	to
O	2223	2230	further
O	2231	2237	marker
O	2237	2238	-
O	2238	2244	driven
O	2245	2252	studies
O	2252	2253	.

O	2254	2263	Treatment
O	2264	2267	was
O	2268	2272	well
O	2273	2282	tolerated
O	2282	2283	.
O	2283	2294	NCT01516307
O	2294	2295	.
